IL101245A0 - Pharmaceutical compositions for the treatment of prostatic cancer - Google Patents

Pharmaceutical compositions for the treatment of prostatic cancer

Info

Publication number
IL101245A0
IL101245A0 IL101245A IL10124592A IL101245A0 IL 101245 A0 IL101245 A0 IL 101245A0 IL 101245 A IL101245 A IL 101245A IL 10124592 A IL10124592 A IL 10124592A IL 101245 A0 IL101245 A0 IL 101245A0
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical compositions
prostatic cancer
prostatic
cancer
Prior art date
Application number
IL101245A
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL101245A0 publication Critical patent/IL101245A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
IL101245A 1991-03-20 1992-03-16 Pharmaceutical compositions for the treatment of prostatic cancer IL101245A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67250691A 1991-03-20 1991-03-20
US84615492A 1992-03-11 1992-03-11

Publications (1)

Publication Number Publication Date
IL101245A0 true IL101245A0 (en) 1992-11-15

Family

ID=27100764

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101245A IL101245A0 (en) 1991-03-20 1992-03-16 Pharmaceutical compositions for the treatment of prostatic cancer

Country Status (5)

Country Link
AU (1) AU1680292A (en)
IE (1) IE920878A1 (en)
IL (1) IL101245A0 (en)
PT (1) PT100255A (en)
WO (1) WO1992016233A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012398A1 (en) * 1993-11-04 1995-05-11 Merck & Co., Inc. 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
WO1993023419A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
IL111467A0 (en) * 1993-11-12 1994-12-29 Merck & Co Inc Pharmaceutical compositions comprising 7 beta -substituted -4-aza 5 alpha -cholestan-3-ones and 5 alpha reductase 1 inhibitors
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
HU223662B1 (en) * 1989-07-07 2004-11-29 Endorecherche Inc. Combination compositions having alpha-reductase inhibitor suitable for preventing and/or treating benign prostatic hyperplasia, kits and process for producing them
AU5851690A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases

Also Published As

Publication number Publication date
PT100255A (en) 1993-09-30
AU1680292A (en) 1992-10-21
WO1992016233A1 (en) 1992-10-01
IE920878A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
IL101243A0 (en) Pharmaceutical compositions for treatment of benign prostatic hyperplasia
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
GB9226832D0 (en) Pharmaceutical preparations for the treatment of psoriasis
IL101410A0 (en) Formulation for the treatment of cancer
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
AU2005692A (en) Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
ZA929879B (en) Compositions for the treatment of mammalian diseases.
ZA943342B (en) The use of compositions for combating tumour diseases
ZA922073B (en) New compounds for use in the treatment of cancer
IL105285A0 (en) Compositions for the treatment of diabetes
IL106763A0 (en) Pharmaceutical compositions for treating cancer
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
IL96455A0 (en) Pharmaceutical compositions for the treatment of hsv
IL105690A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
GB9219776D0 (en) New compounds for use in the treatment of cancer
IL115200A0 (en) Pharmaceutical compositions for the treatment of cancer
GB9123572D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
EP0460690A3 (en) Use of phenolsulfophthaline derivatives for the treatment of osteoporosis
GB9024181D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
GB9117210D0 (en) Treatment of cancer
IL86116A0 (en) Pharmaceutical compositions for the treatment of malaria